On Monday, May 13, the U.S. Food and Drug Administration (FDA) will be holding a public hearing on biosimilar insulin.
A biosimilar is a biological product that is very similar to a reference product, and considered to have no differences that would change what would be expected from the reference product. The FDA is “holding this public hearing to receive input from stakeholders as the Agency prepares for the submission and review of applications for biosimilar and interchangeable insulin products. FDA anticipates that these products, once they are approved, will bring new competition to the insulin market and help provide affordable treatment options to patients with diabetes.”
The hearing will be taking place at 10903 New Hampshire Avenue, Silver Spring, Maryland. To register to attend, either in-person or online, visit this Eventbrite webpage, and to watch the webcast, visit the FDA website.
Want to learn more about biosimilar insulin? Read “When Will There Be Generic Insulin?”